Sign in →

Test Code HI/MOD Risk   Common Cancer Managment Panel  

Performing Laboratory

BioReference- GeneDx

Methodology

  • Deletion/Duplication Analysis
  • Next-Gen Sequencing
  • MLPA

Reference Values

See Report

 

Includes Genes:

APC, ATM, AXIN2, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDKN2A, CHEK2, EPCAM, FH, FLCN, MLH1, MSH2, MSH6, MUTYH, NBN, NF1, NTHL1, PALB2, PMS2, POLD1, POLE, PTEN, RAD51C, RAD51D, SCG5/GREM1, SDHB, SDHC, SDHD, SMAD4, STK11, TP53, TSC1, TSC2, VHL

 

 

Physician Office Specimen Requirements

Container/Tube:  Lavender top tube

Specimen: 2 - 5 mL whole blood

Transport Temperature: Room Temperature

Computer Interface Code

PDM #  1659844

Useful For

  • The differential diagnosis includes various hereditary cancer syndromes. For example, if the family history consists of multiple cases of ovarian cancer, this may be associated with a breast/ovarian cancer syndrome such as BRCA1 or BRCA2 or Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM). Thus, the OncoGeneDx High/Moderate Risk Panel offers increased clinical sensitivity compared to testing only for the BRCA genes. Furthermore, panel testing is more cost effective than stepwise genetic testing (for example, ordering BRCA testing followed by additional genetic testing).
  • The family history includes a number of cancer cases, but they are of several different types. Therefore, the pattern does not seem to fit any one hereditary cancer syndrome in particular.
  • Some genetic testing has already been ordered due to a family history suggestive of a hereditary cancer predisposition, and results have been negative. OncoGeneDx High/Moderate Risk Panel includes three recently described, but well-studied, cancer predisposition genes (ATM, CHEK2, PALB2) in addition to genes associated with classic hereditary cancer syndromes, and may allow for detection of a causative mutation after initial testing is uninformative

CPT Coding

81162

81201

81203

81292

81294

81295

 

TAT; 14 Days